(S,S)-GSK321

  Cat. No.:  DC72374  
Chemical Structure
1816272-20-4
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
(S,S)-GSK321 is a (S,S)-enantiomer of GSK321.
Cas No.: 1816272-20-4
Chemical Name: (S,S)-GSK321
SMILES: C[C@H](O)C1=CC=CC(NC(C2=NN(C3=C2CN(C[C@@H]3C)C(C4=CC=CN4)=O)CC5=CC=C(C=C5)F)=O)=C1
Formula: C28H28FN5O3
M.Wt: 501.55
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
MSDS
TITLE DOWNLOAD
MSDS_36825_DC72374_1816272-20-4
COA
LOT NO. DOWNLOAD
Cat. No. Product name Field of application
DC44726 Enasidenib Mesylate Enasidenib (Idhifa, AG-221) mesylate is an orally available, selective and potent inhibitor of mutant isocitrate dehydrogenase 2 (IDH2).
DC28576 DS-1001b DS-1001b is a mutant IDH-1 (Isocitrate Dehydrogenase-1) inhibitor extracted from patent WO2016052697A1, Example 168, and has antitumor activity.
DC72374 (S,S)-GSK321 (S,S)-GSK321 is a (S,S)-enantiomer of GSK321.
DC70642 NCATS-SM5637 NCATS-SM5637 (NSC 791985) is a potent, selective mutant IDH1 inhibitor with IC50 of 81/72 nM for IDH1 mutant R132H/R132C, respctively.NCATS-SM5637 showed higher tumoral concentrations that corresponded to lower 2-HG concentrations in engineered mIDH1-U87-xenograft mouse model, compared with the approved drug AG-120 (ivosidenib).
DC49742 AGI-12026 AGI-12026 is brain-penetrant dual inhibitor of mutant IDH1 and 2. AGI-12026 shows partial inhibition of the IDH1-R132H homodimer as allosteric modulators. AGI-12026 has the potential for research of glioma.
DC48219 Safusidenib Safusidenib is a novel IDH1 inhibitor for the treatment of IDH1-mutated tumors.
X